Migraine is a common primary headache disorder characterized by recurrent attacks of moderate to severe headache often accompanied by nausea, photophobia, and phonophobia. It contributes substantially to disability worldwide.
The White House reports a 3.1% drop in prescription drug prices over the past year, the steepest decline since 1963, attributing it to President Trump's Most Favored Nation policies and TrumpRx discounts. Drugmakers like Pfizer have agreed to significant price cuts on several medications.
Insilico Medicine named ISM9528 as its 31st AI-driven preclinical pain candidate, published a target discovery study for a rare sinonasal cancer, and advanced partnerships with MSK and Takeda. The company is also presenting oncology programs at AACR 2026.
AbbVie's Q2 2026 revenue hit $16.99 billion, beating estimates, but full-year EPS guidance was cut to $13.97. Growth in immunology and neuroscience continued, and the FAST study on ubrogepant wrapped up.
AbbVie posted record 2025 revenue of $61.2 billion and raised 2026 guidance on Skyrizi and Rinvoq growth. Pipeline advances include Crohn's submissions, obesity data, and European approval for Boey.
A study using FAERS and MEPS data found that oral contraceptive side effects such as acne, migraine, anxiety, and depression vary by progestin type. Drospirenone-containing pills had higher reported rates of all four, while acne was also greater with levonorgestrel and norgestimate.
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
AbbVie posted record full-year 2025 revenue of $61.2B and raised its 2026 outlook after strong Q1 Skyrizi and Rinvoq sales. Phase 3 AFFIRM data and new FDA submissions highlight pipeline progress, while full-year revenue guidance was lifted to $67.3B.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
The FDA has announced plans to crack down on active pharmaceutical ingredients used in compounded GLP-1 drugs and warned about the risks of these products. The agency has cited counterfeit products, non-FDA-approved ingredients and more than 1,000 adverse event reports tied to compounded semaglutide and tirzepatide.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779486 |
High- vs Standard-Dose Intravenous Magnesium for Acute Headache |
RECRUITING | NA |
| NCT07772427 |
Neuromodulation During the Prodrome to Prevent Disabling Migraine Attacks in Youth |
NOT_YET_RECRUITING | NA |
| NCT07764783 |
Visual Instillation of Sphenopalatine-block Intervention for ONgoing Migraine |
NOT_YET_RECRUITING | PHASE2 |
| NCT07754266 |
Headache Ear Auditory Dizziness Sinus (HEADS) Registry |
RECRUITING | |
| NCT07720895 |
Default Mode Network Connectivity and Nocebo Responses in Migraine: A Functional MRI Study |
COMPLETED | NA |
| NCT07720765 |
Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N) |
RECRUITING | |
| NCT07699549 |
Long-term Atogepant in Real-world Practice |
COMPLETED | |
| NCT07698249 |
Headache Diary for Migraine Patients |
ENROLLING_BY_INVITATION | NA |
| NCT07694063 |
Online Hatha Yoga Program as an Add-On Therapy for Episodic High-Frequency Migraine |
RECRUITING | NA |
| NCT07690696 |
Tear Biomarkers for Migraine |
NOT_YET_RECRUITING |
